Category: Health

High-dose vitamin B3 may enhance immune function and slow the progression of glioblastoma, with 82% of trial patients showing no disease progression after six months, according to a recent study.

High-dose vitamin B3, commonly known as niacin, may significantly boost immune function and improve short-term disease control in patients with glioblastoma when used alongside standard therapies, according to early preclinical studies.

Glioblastoma is a highly aggressive and fast-growing brain cancer that originates from cells in the brain and spinal cord. Previous laboratory experiments conducted on mice indicated that niacin could extend survival rates. Researchers at the University of Calgary sought to determine whether these benefits could also be observed in humans.

The clinical trial included 24 patients diagnosed with glioblastoma, a condition that typically has a median survival rate of approximately 12 to 18 months. Remarkably, six months after receiving niacin in conjunction with standard treatments—surgery, radiation, and chemotherapy—82% of the patients exhibited no disease progression. This is a notable increase compared to the typical 54% of patients who experience no progression under standard treatment alone, as reported in the study’s press release.

Additionally, niacin was found to restore functionality in weakened immune cells, enhancing their ability to target and eliminate tumor cells. The findings, which highlight a 28% improvement in disease progression, were published in the Journal of Neuro-Oncology.

“Normally, the immune system attempts to counter and prevent tumor growth; however, glioblastoma actively suppresses the immune response,” said Dr. Wee Yong, PhD, a neuroscientist involved in the study. “Niacin treatment rejuvenates immune cells so they can perform their essential functions: attacking and destroying cancer cells. I view this as an ongoing ‘battle for the brain.’”

Looking ahead, the research team plans to enroll an additional 24 patients by the end of 2026 or early 2027 for the next phase of the trial, which will focus on assessing niacin’s safety and its effects on immune system activation.

Dr. Marc Siegel, a senior medical analyst at Fox News, noted that previous studies have demonstrated that vitamin B3 can reduce inflammation and enhance immune function. “Vitamins, including the B vitamins—especially niacin—are often underrecognized as immune boosters,” he stated, although he was not involved in the study.

Despite these promising early results, the researchers have urged caution regarding the implications of their findings. “Glioblastoma is the most aggressive brain cancer in adults, and patient survival rates have not significantly improved in the past two decades,” said lead study author Roldan Urgoiti, a clinical associate professor at the CSM. “While any potential treatment that may help should be explored, it requires strict protocols and safety monitoring.”

The study’s limitations include its small sample size, short follow-up period, and the absence of a randomized control group. The researchers emphasized the need for larger, controlled trials to verify their findings.

Furthermore, the researchers cautioned that high doses of vitamins can pose health risks, and any supplementation should be closely monitored by healthcare professionals. Dr. Siegel also acknowledged that niacin can have side effects, such as skin flushing. “While there may be a small impact here, this information is useful, though it is clearly not a cure,” he added.

As the research progresses, the scientific community remains hopeful that niacin could play a role in enhancing treatment options for glioblastoma patients, but further investigation is essential to fully understand its potential benefits and risks.

According to Fox News, the ongoing exploration of vitamin therapies in cancer treatment represents a promising avenue for improving patient outcomes in the face of challenging diagnoses.

Clinical trials are essential to medical advancements, yet misconceptions and lack of awareness hinder participation, impacting the development of new treatments and therapies.

Clinical trials serve as the cornerstone of medical advancements, leading to breakthroughs in cancer treatments, vaccines, and diagnostic tools. However, many people remain unaware of their significance until faced with a serious health diagnosis. This gap in knowledge, combined with prevalent misconceptions, can have serious consequences. It can slow the progress of promising treatments, prevent patients from accessing cutting-edge care, and limit the applicability of trial results due to a lack of diverse participants.

One of the most common misconceptions surrounding clinical trials is that they are only for patients with severe illnesses, leading to the belief that medical professionals recommend trials only when there is little hope left. Additionally, the fear of being treated as a “guinea pig” is a widespread concern that transcends various patient populations, regardless of their previous research experiences. Many potential participants worry that they might receive a placebo, rendering their involvement ineffective.

According to the clinical center at the National Institutes of Health (NIH), only about 1% of the U.S. population participates in clinical trials. Paradoxically, nearly 80% of the general public holds a positive view of clinical research, despite these fears and misconceptions. Professor Lisa Goldman Rosas, an expert in Epidemiology and Population Health at Stanford’s School of Medicine, notes, “Community mistrust and lack of awareness are major barriers to participation in clinical trials, particularly in underrepresented communities. History plays a big role, and we have to work hard to educate the community and gain people’s trust.”

So, what exactly is a clinical trial? Clinical trials are meticulously designed research studies aimed at testing new medical interventions—such as drugs, devices, procedures, or preventive measures—to assess their safety and effectiveness before they become widely available. These trials are crucial for advancing medical research and developing new treatments. Every prescribed medication in the U.S. has undergone this rigorous testing process, which can take a decade or longer before receiving approval from the Food and Drug Administration (FDA).

In clinical trials, human subjects are assigned to one or more interventions, which may include a placebo or other control, to evaluate the effects on health-related biomedical or behavioral outcomes. Each study follows a predefined, reviewed, and approved process outlined in a written protocol, detailing how subjects will be assigned to different groups or “arms” of the trial.

A fundamental principle in clinical trial design is that the welfare of participants must always take precedence over the interests of science and society. Ethical considerations are paramount, and all trial protocols undergo ethical review and oversight by independent Institutional Review Boards, as mandated by federal law for all clinical research involving human subjects in the U.S. and many other countries.

There are various types of clinical trials. Approximately 25% are observational, where researchers monitor and record data without intervening. The landmark Framingham Heart Study, which began in 1948, is a prime example, tracking over 5,000 residents of Framingham, Massachusetts, to identify major cardiovascular disease risk factors. The remaining 75% of trials test medical interventions, with about 40% focused on drugs, medications, or vaccines, and 10% on medical devices such as implants and surgical instruments.

Drug development typically involves several phases, each with distinct objectives. The initial phase tests safety and dosage in small groups to explore optimal dosing and short-term toxicity. If a safe dose range is identified, the trial progresses to Phase II, which evaluates effectiveness and side effects in larger groups, typically composed of subjects with the condition being addressed. This phase must demonstrate that the treatment yields clinically meaningful results to justify further investment in the trials.

Phase III trials compare the new treatment to a placebo, current standard care, or other treatment modalities in large populations. These high-stakes trials account for 50-70% of total clinical development costs, and only about one in three drugs advances to this phase. What appears promising in earlier testing may not translate to clinical benefit.

Once Phase III is completed and regulatory approval is obtained, Phase IV trials monitor the real-world use of the new drug, device, or intervention, utilizing observational data from medical records, registries, or adverse-event databases.

The role of volunteers in clinical trials is vital. Trials investigating interventions for specific conditions need to enroll patients with those conditions, while prevention trials may involve individuals at risk for those conditions. By assembling a representative group of volunteers, researchers can ensure that the results are applicable to the broader community.

Healthy volunteers also play a crucial role in clinical research. For most new medications, excluding those for cancer and certain toxic biologics, healthy individuals can participate in Phase I trials to establish safety profiles, determine appropriate dosing ranges, and study how drugs are absorbed and metabolized in the body. Their contributions provide essential baseline data that helps researchers distinguish drug effects from disease symptoms in patient populations.

Nearly 60% of healthy volunteers cite societal benefits as their primary motivation for participation, recognizing that their involvement accelerates medical advancements that will ultimately benefit future patients, including their loved ones. By volunteering before facing health challenges themselves, these individuals help establish safety standards that protect all future clinical trial participants and expedite the delivery of promising treatments to those in need.

Clinical trials should be viewed as a social good, essential to enhancing health, extending life, and alleviating the burdens of illness and disability. Increased knowledge and awareness of clinical trials can help individuals understand the true benefits and risks, make informed decisions about participation, and advocate for clinical research within their communities.

As Dr. Francis Collins, a distinguished physician-geneticist and former Director of the NIH, stated, “Signing up for a clinical trial may benefit medical research and help future generations. But it is not strictly an altruistic endeavor. In many instances, trial participants do gain personal advantages, such as improved disease outcomes or better health.”

Understanding clinical trials is crucial for fostering participation and advancing medical research that can lead to innovative treatments and improved health outcomes for all.

Deepanwita Dasgupta, diagnosed with subacute sclerosing panencephalitis after contracting measles at age five, highlights the severe long-term risks associated with the virus.

Deepanwita Dasgupta’s journey began when she was just five years old, playing at her home in Bangalore, India. Her parents noticed that she was stumbling more often, attributing the extra bumps and bruises to her active nature. They thought perhaps her shoes were ill-fitting.

Described by relatives as smart, affectionate, and occasionally mischievous, Deepanwita had a knack for technology, managing to find her favorite show, *Blippi*, on a phone before she even learned the alphabet. She was known for sneaking butter from the fridge for a quick taste.

However, her playful childhood took a drastic turn when her limbs began to jerk uncontrollably. A spinal tap revealed the presence of the measles virus in her cerebrospinal fluid. The virus, contracted during her infancy, had silently made its way to her brain. Now, at eight years old, Deepanwita is paralyzed and unable to speak.

Measles is notorious for causing a range of complications, from diarrhea to death, affecting approximately three in ten infected individuals, according to the Infectious Diseases Society of America. While some complications arise immediately, others may take weeks or even months to manifest. Deepanwita’s condition, known as subacute sclerosing panencephalitis (SSPE), typically takes years to develop.

“People think, ‘Oh, you know, if we get measles, then we’ll be fine, because I know my neighbor had it and they’re fine,’” said Yasmin Khakoo, a leading neurologist in New York City. Khakoo emphasized the dangers of measles, noting that a seven-year-old in South Carolina had to relearn how to walk due to brain swelling, another immediate complication of the virus. In some cases, measles can plant a ticking time bomb in the nervous system, allowing individuals to appear healthy for years before severe problems arise. While some patients may experience temporary disabilities, the condition is almost always fatal.

Before the widespread availability of effective vaccines, SSPE was a common complication in the U.S. In the 1960s, a doctor established a national registry for SSPE patients. Current estimates suggest that about one in 10,000 individuals who contract measles will develop SSPE, with the risk significantly elevated for those infected before the age of five. Countries where measles is endemic, such as India, continue to see regular cases.

As vaccination rates decline and measles outbreaks increase in the U.S., medical professionals are concerned that cases of SSPE will also rise. Since the beginning of 2025, the Centers for Disease Control and Prevention has reported over 3,500 measles cases, surpassing the total from the previous decade, predominantly among unvaccinated individuals, many of whom are children. Last year, a six-year-old in Connecticut was diagnosed with SSPE, and a school-aged child in California died from the condition after contracting measles as an infant.

“We are likely to see SSPE cases going forward, especially if we don’t get this under control,” warned Adam Ratner, a member of the American Academy of Pediatrics’ Committee on Infectious Diseases.

In response to growing concern, the Child Neurology Society published a video in January to educate U.S. clinicians about SSPE, and physicians who have encountered such cases are urging their colleagues to be vigilant.

“We don’t have a way of knowing who’s going to get it, and we don’t have a way of very effectively treating it,” said Aaron Nelson, a professor of neurology at New York University. “The one best thing that we can do, ideally, is to prevent children from having to go through it in the first place.”

The recommended two-dose measles vaccine significantly reduces the risk of contracting the virus, lowering it from 90% to just 3%, thereby decreasing the likelihood of developing SSPE. While the vaccine carries minor risks, such as febrile seizures and a bleeding condition, the risks associated with measles itself are far greater.

Deepanwita’s story is a poignant reminder of the potential consequences of measles. In 2022, she celebrated her fifth birthday, unaware that her health would soon take a tragic turn. At her eighth birthday gathering, Deepanwita, dressed in a pink eyelet dress and supported by a nasal tube, could only blink and move her eyes as she sat before two cakes she could not eat.

Roberto Cattaneo, a molecular biologist at the Mayo Clinic, has been studying SSPE for years. He recently utilized postmortem brain tissue to investigate how the measles virus spreads within the brain. Despite his research, he acknowledges that the exact mechanisms of the virus during the dormant period between initial infection and the onset of neurological symptoms remain largely unknown.

“The problem could be solved with vaccination,” Cattaneo stated, expressing frustration that such a preventable condition still exists. “The U.S. should have no cases of SSPE. It’s just painful.”

As the number of measles outbreaks rises globally, the situation remains dire, particularly in countries like India. In New Delhi, Sheffali Gulati, a pediatric neurologist, sees about ten new SSPE patients each year, referring to the condition as a “delayed echo” of measles outbreaks. The youngest patient she has treated was just three years old.

With families like Deepanwita’s facing the harsh realities of SSPE, the urgent need for vaccination and awareness has never been clearer. The long-term effects of measles can be devastating, and the medical community continues to advocate for prevention to protect future generations.

According to KFF Health News, the importance of vaccination cannot be overstated in the fight against measles and its severe complications.

Vitamin D supplements may reduce the risk of long COVID symptoms, such as fatigue and brain fog, according to a recent study conducted by researchers at Mass General Brigham.

A new study suggests that vitamin D supplements could play a role in alleviating long COVID symptoms, which persist after the initial infection. Researchers at Mass General Brigham investigated whether high doses of vitamin D could affect COVID-19 outcomes, particularly the risk of developing long COVID, a condition characterized by lingering symptoms such as fatigue, shortness of breath, and brain fog. The findings were published in The Journal of Nutrition.

The randomized clinical trial involved 1,747 adults who had recently tested positive for COVID-19, along with 277 members of their households. Participants were assigned to receive either vitamin D3 supplements or a placebo for a duration of four weeks.

Dr. JoAnn Manson, the senior author of the study and a physician at Mass General Brigham, highlighted the potential benefits of vitamin D supplementation for long-term symptoms. “A key takeaway is that vitamin D supplementation looks promising for reducing the risk of developing long COVID but does not appear to affect the severity of the acute infection,” Manson stated.

While the study found that vitamin D supplementation did not significantly alter short-term outcomes, such as symptom severity or the need for hospital visits, a closer examination of participants who adhered to the supplement regimen revealed a noteworthy difference in lingering symptoms. Approximately 21% of those who took vitamin D reported at least one ongoing symptom eight weeks after infection, compared to 25% of participants who received a placebo.

“There’s been tremendous interest in whether vitamin D supplements can be of benefit in COVID, and this is one of the largest and most rigorous randomized trials on the subject,” Manson remarked in a press release. “While we didn’t find that high-dose vitamin D reduced COVID severity or hospitalizations, we observed a promising signal for long COVID that merits additional research,” she added.

Manson explained that vitamin D may influence longer-term complications due to its role in regulating inflammation within the body. However, the researchers acknowledged several limitations in the trial. The study had to be conducted remotely during the pandemic, and participants began taking vitamin D several days after their COVID diagnosis.

Ideally, Manson noted, supplementation should commence before infection or immediately following diagnosis. She emphasized the need for larger studies to confirm whether vitamin D could effectively reduce the risk or severity of long COVID symptoms.

Researchers are planning additional trials to further explore the potential of vitamin D supplementation in treating individuals already experiencing long COVID.

These findings provide a promising avenue for future research and may offer hope for those grappling with the long-term effects of COVID-19, according to Fox News.

A groundbreaking blood test could identify dementia risk in women up to 25 years before symptoms appear, according to research from the University of California San Diego.

Researchers from the University of California San Diego have developed a blood test that may determine a woman’s risk of developing dementia as early as 25 years before any symptoms manifest. This promising finding centers on a specific biomarker protein associated with the early pathological processes of Alzheimer’s disease, known as phosphorylated tau 217 (p-tau217).

The study analyzed blood samples from 2,766 participants in the Women’s Health Initiative Memory Study, conducted in the late 1990s. The participants, aged between 65 and 79, exhibited no signs of cognitive decline at the study’s outset. Over a follow-up period of up to 25 years, researchers found a strong association between elevated levels of p-tau217 and future instances of mild cognitive impairment and dementia.

Women with higher levels of p-tau217 at the beginning of the study were significantly more likely to develop dementia later on. The findings were published in JAMA Network Open, highlighting the potential for early detection of dementia risk through a simple blood test.

“The key takeaway is that our study suggests it may be possible to detect risk of dementia two decades in advance using a simple blood test in older women,” said Aladdin H. Shadyab, the study’s first author and an associate professor of public health and medicine at UC San Diego. “Our findings show that the blood biomarker p-tau217 could help identify individuals at higher risk for dementia long before symptoms begin.”

This early detection could pave the way for preventive strategies and targeted monitoring, allowing for interventions before memory issues disrupt daily life. Shadyab emphasized that as research progresses, these biomarkers could help pinpoint individuals at the greatest risk and inform strategies to delay or prevent dementia.

However, the relationship between p-tau217 levels and dementia risk was not uniform across all demographics. The study indicated that women over 70 with elevated p-tau217 levels experienced poorer cognitive outcomes compared to their younger counterparts. Additionally, those with the APOE ε4 gene, a known risk factor for Alzheimer’s disease, also showed a stronger correlation between p-tau217 levels and cognitive decline.

Interestingly, the study revealed that p-tau217 was a more significant predictor of dementia in women who were randomly assigned to receive estrogen and progestin hormone therapy, compared to those who received a placebo. This finding suggests that hormonal factors may play a role in the relationship between p-tau217 levels and dementia risk.

Senior author Linda K. McEvoy, a senior investigator at Kaiser Permanente Washington Health Research Institute and professor emeritus at the Herbert Wertheim School of Public Health, noted the advantages of blood-based biomarkers like p-tau217. “Blood-based biomarkers like p-tau217 are especially promising because they are far less invasive and potentially more accessible than brain imaging or spinal fluid tests,” she explained. “This is important for accelerating research into the factors that affect the risk of dementia and for evaluating strategies that may reduce risk.”

Despite the promising nature of these findings, Shadyab cautioned that blood tests for Alzheimer’s disease are still under investigation and are not yet recommended for routine screening in asymptomatic individuals. Further research is necessary before this approach can be considered for clinical use prior to the onset of cognitive symptoms.

Future studies should explore how various factors, including genetics, hormone therapy, and age-related medical conditions, may interact with plasma p-tau217 levels. Shadyab also pointed out that the study focused exclusively on older women, indicating that the findings may not be applicable to men or younger populations. Additionally, the research examined overall dementia outcomes rather than specific subtypes, such as Alzheimer’s disease.

As the understanding of dementia risk factors evolves, the potential for early detection through blood tests like p-tau217 may revolutionize the approach to managing and preventing this debilitating condition.

According to Fox News Digital, the implications of this research could significantly impact future dementia prevention strategies.

Compounds in cannabis, particularly cannabidiol (CBD) and cannabigerol (CBG), may offer new treatment options for metabolic dysfunction-associated steatotic liver disease, a common chronic liver condition affecting many adults worldwide.

Research from the Hebrew University of Jerusalem suggests that compounds found in cannabis could pave the way for innovative treatments for the world’s most prevalent chronic liver disorder. The study, published in the British Journal of Pharmacology, highlights the potential of cannabidiol (CBD) and cannabigerol (CBG) in reducing liver fat and enhancing metabolic health in experimental models.

CBD is the more extensively researched non-intoxicating cannabinoid, while CBG serves as a precursor cannabinoid from which CBD is derived. Unlike THC, the primary psychoactive component of cannabis, both CBD and CBG do not induce a “high,” making them promising candidates for long-term medical applications.

Metabolic dysfunction-associated steatotic liver disease (MASLD) currently impacts approximately one-third of the global adult population, as indicated by health data. This condition is closely associated with obesity and insulin resistance, yet there are few approved pharmaceutical treatments available. Consequently, patients often rely on challenging lifestyle changes to manage their condition.

Lead study author Joseph Tam, director of the Multidisciplinary Center for Cannabinoid Research at Hebrew University, stated, “Our findings identify a new mechanism by which CBD and CBG enhance hepatic energy and lysosomal function.”

The research emphasizes a process known as “metabolic remodeling,” where the cannabis compounds create a “backup battery” for the liver by increasing levels of phosphocreatine, a high-energy molecule stored in muscle cells. This energy reserve enables the liver to function more effectively under the stress of a high-fat diet, an unexpected finding noted by the research team.

Additionally, the study revealed that CBD and CBG restored the activity of “cellular cleaning crews,” known as cathepsins. These enzymes operate within the cell’s recycling centers to break down harmful fats and waste. As a result, the liver became more adept at clearing dangerous lipids, including triglycerides and ceramides, which are known to cause inflammation.

While both CBD and CBG demonstrated effectiveness, CBG yielded more pronounced results in specific areas, such as reducing total body fat mass, lowering “bad” LDL cholesterol, and improving insulin sensitivity. The researchers believe this study opens new avenues for utilizing plant-based compounds to treat metabolic diseases by focusing on cellular energy management and waste disposal.

Despite these promising findings, the research team cautioned that the study was conducted in a controlled experimental setting. Further clinical trials are essential to ascertain the appropriate application of these compounds for human patients.

Recent studies have also raised concerns regarding the use of cannabis as a medical treatment. A major analysis published in JAMA examined over 2,500 scientific papers from the past 15 years, including reviews, clinical trials, and guidelines related to medical marijuana. This review underscored significant discrepancies between public perception and scientific evidence regarding the effectiveness of cannabis for various medical conditions.

The researchers concluded that only a limited number of conditions have clear, well-established benefits from cannabinoid therapies supported by high-quality clinical data. “Whenever a substance is widely used, there is likely to be a very wide set of outcomes,” noted Dr. Alex Dimitriu, who is double board-certified in psychiatry and sleep medicine. He emphasized that this study illustrates the reality that cannabis is not a universal remedy.

The strongest evidence currently supports FDA-approved cannabinoid medications for treating specific conditions, including appetite loss related to HIV/AIDS, chemotherapy-induced nausea and vomiting, and certain severe pediatric seizure disorders.

Individuals interested in exploring marijuana for medical purposes are encouraged to consult with a healthcare provider to discuss potential risks and benefits, ensuring informed decision-making regarding their health.

According to Fox News, the implications of this research could significantly impact the future treatment landscape for liver diseases.

Recent studies indicate that GLP-1 drugs, including Ozempic and Wegovy, may increase fracture risk and osteoporosis in older adults with Type 2 diabetes, prompting calls for closer monitoring of bone health.

A new study suggests that GLP-1 medications, such as Ozempic and Wegovy, may elevate the risk of fractures by 11% in adults aged 65 and older who have Type 2 diabetes, compared to those using other diabetes treatments.

These GLP-1 drugs have revolutionized the management of Type 2 diabetes and obesity, but recent findings indicate that healthcare providers should be more vigilant regarding bone health in older patients prescribed these medications. A study published in February in the Journal of Clinical Endocrinology & Metabolism revealed that older adults with Type 2 diabetes who began using GLP-1 medications experienced a statistically significant increase in the risk of fragility fractures.

Dr. Michal Kasher Meron, an endocrinologist at Meir Medical Center in Israel and the study’s lead author, emphasized that while an 11% increase may seem modest, it is significant for a vulnerable population. “Both older age and Type 2 diabetes are independent risk factors for fragility fractures,” she stated. “This is a population that deserves special attention.”

Fragility fractures are typically caused by minor falls or routine activities and are often associated with osteoporosis. Such fractures can lead to hospitalization, loss of independence, and even increased mortality among older adults, according to Dr. Kasher Meron.

The study monitored over 46,000 adults aged 65 and older for nearly three years. After making necessary adjustments, researchers found that those using GLP-1 medications had a modest but statistically significant increase in fracture risk.

Previous studies involving younger patients using older GLP-1 medications did not indicate an increased fracture risk. However, the newer and more potent versions are now commonly prescribed to older adults, which alters the risk landscape. “In older adults treated with contemporary medications, the fracture risk picture looks different and warrants close attention,” Dr. Kasher Meron noted.

It is important to highlight that the study was observational, indicating an association rather than causation. Researchers could not ascertain whether the increased risk was due to weight loss, dietary changes, muscle loss, or a direct effect on bone health.

Despite these findings, Dr. Kasher Meron advocates for assessing bone health before initiating GLP-1 medications in older patients rather than treating it as an afterthought. The study’s results coincide with additional research presented at the American Academy of Orthopaedic Surgeons’ annual meeting, which raised further concerns regarding bone health.

In an analysis of over 146,000 adults with obesity and Type 2 diabetes, those using GLP-1 medications were found to have a 29% higher relative risk of developing osteoporosis over five years compared to nonusers. Additionally, rates of gout were slightly elevated, affecting 7.4% of GLP-1 users versus 6.6% of nonusers, representing a 12% relative increase. Osteomalacia, a condition characterized by softening of the bones, was rare but occurred approximately twice as often in GLP-1 users, according to the study, which has not yet undergone peer review.

Experts suggest several mechanisms may contribute to these findings. GLP-1 medications suppress appetite and can lead to rapid weight loss, which is known to reduce bone density. This reduction occurs partly because less mechanical load is placed on the skeleton. Dr. John Horneff, an associate professor of orthopedic surgery at the University of Pennsylvania, likened this phenomenon to astronauts experiencing low bone density after extended periods in a zero-gravity environment.

Moreover, a decrease in caloric intake may result in lower consumption of calcium, vitamin D, and protein—nutrients essential for maintaining bone strength. Rapid weight loss can also temporarily elevate uric acid levels, a byproduct of tissue breakdown, potentially explaining the rise in gout cases.

Despite these concerns, experts caution against discouraging the appropriate use of GLP-1 medications, which have demonstrated significant benefits for blood sugar control, weight loss, and cardiovascular risk reduction. In addition to bone density screenings, experts recommend that patients ensure adequate nutrition and engage in resistance training to help preserve muscle and bone during weight loss.

A spokesperson for Novo Nordisk, the manufacturer of GLP-1 medications, stated that the company prioritizes patient safety and collaborates closely with the U.S. Food and Drug Administration (FDA). Liz Skrbkova, head of U.S. media relations for Novo Nordisk, emphasized that the known risks and benefits of these drugs are reflected in the current FDA-approved labeling. She noted that semaglutide, one of the GLP-1 medications, has shown cardiovascular, kidney, and liver benefits when used under medical supervision.

“Osteoporosis is a complex condition that develops over many years as a result of interdependent risk factors,” Skrbkova added.

These findings underscore the need for healthcare providers to closely monitor bone health in older adults prescribed GLP-1 medications, ensuring that the benefits of these treatments are balanced with potential risks.

According to Fox News Digital, the implications of these studies are significant for the management of diabetes and obesity in older populations.